Withdrawn
PHASE2
INTERVENTIONAL
NCT01714089
Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to determine whether RNS60 is effective in the treatment of RR-MS compared to interferon beta-1a.
Interventions
Name:
RNS60 125 ml
Type:
DRUG
Description:
Name:
RNS60 250 ml
Type:
DRUG
Description:
Name:
Interferon beta 1a
Type:
DRUG
Description:
Primary Outcomes
Measure:
Change in number of GAD-enhancing lesions from baseline
TimeFrame:
3, 4, 5, and 6 months
Description:
Cumulative number of GAD-enhancing lesions by MRI at months 3, 4, 5, and 6
Trial Information
NCT ID
NCT01714089
Status
Withdrawn
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Revalesio Corporation
Last Updated
December 15, 2025